Clinical trial
CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
NCT05131828 is registered in ClinicalTrials.gov with Cambridge University Hospitals NHS Foundation Trust as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
- Lead sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 8, 2022
- Completion date
- September 26, 2025
- Enrollment
- 70 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.